| Availability: | |
|---|---|
PREJUVA®
What is Prejuva?
Prejuva muscle base cell activation course injection, commonly known as hyaluronic acid counterclockwise. Prejuva is characterized by a mixture of high molecular weight and low molecular weight hyaluronic acid; Thicker and slow-metabolizing polymer hyaluronic acid is injected into the 5-point facial position according to the aesthetic principle to establish a long-lasting dermis layer scaffold, support the loose skin, stimulate the regeneration of collagen and elastin at the injection site, and assist in achieving the lifting effect; simultaneous use of low molecular weight hyaluronic acid, Spread evenly over the face to achieve the effect of facial hydration. And through heat energy cross-linking, without cross-linking agent BDDE, it can reshape and firm facial skin and moisturize facial cells.
What is PREJUVA?
PREJUVA® constitutes a buffered physiological solution of high molecular weight (H-HA) and low molecular weight (L-HA) HA. The HA, at both high and low molecular weights used in the device, is obtained through a biofermentation process without chemical modification and therefore, resulting in excellent tolerability.
Furthermore, due to a specific and patented treatment of the solution (HYLAFUSE Technology TM), the H-HA and L-HA chains, contained in PREJUVA®, interact with each other providing unique rheological characteristics and thus allowing the administration of higher concentrations of HA without increasing the viscosity
Dermax Co., Ltd. is a biotechnology enterprise specialized in the research, production and sale of aesthetic products. The establishment of professional technical team, GMP production plant, complete and strict testing system has guaranteed stable and advanced manufacturing technique. The high quality, integrity and global marketing network enable our company to win high praise home and abroad including in Europe, America, Southeast Asia etc.
What is Prejuva?
Prejuva muscle base cell activation course injection, commonly known as hyaluronic acid counterclockwise. Prejuva is characterized by a mixture of high molecular weight and low molecular weight hyaluronic acid; Thicker and slow-metabolizing polymer hyaluronic acid is injected into the 5-point facial position according to the aesthetic principle to establish a long-lasting dermis layer scaffold, support the loose skin, stimulate the regeneration of collagen and elastin at the injection site, and assist in achieving the lifting effect; simultaneous use of low molecular weight hyaluronic acid, Spread evenly over the face to achieve the effect of facial hydration. And through heat energy cross-linking, without cross-linking agent BDDE, it can reshape and firm facial skin and moisturize facial cells.
What is PREJUVA?
PREJUVA® constitutes a buffered physiological solution of high molecular weight (H-HA) and low molecular weight (L-HA) HA. The HA, at both high and low molecular weights used in the device, is obtained through a biofermentation process without chemical modification and therefore, resulting in excellent tolerability.
Furthermore, due to a specific and patented treatment of the solution (HYLAFUSE Technology TM), the H-HA and L-HA chains, contained in PREJUVA®, interact with each other providing unique rheological characteristics and thus allowing the administration of higher concentrations of HA without increasing the viscosity
Dermax Co., Ltd. is a biotechnology enterprise specialized in the research, production and sale of aesthetic products. The establishment of professional technical team, GMP production plant, complete and strict testing system has guaranteed stable and advanced manufacturing technique. The high quality, integrity and global marketing network enable our company to win high praise home and abroad including in Europe, America, Southeast Asia etc.
Interest in buttock contouring has increased substantially in recent years. Data from the International Society of Aesthetic Plastic Surgery indicate that aesthetic procedures involving the buttocks rose by more than 60% between 2019 and 2023. While surgical approaches such as implants and autologou
Polynucleotide treatment aftercare is often the deciding factor between average outcomes and consistently refined, stable results in clinical practice. Even with well-executed injection techniques, improper post-treatment management may compromise skin recovery, patient comfort, and the overall rege
